| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
In addition, today Xilio announced the achievement of a $17.5 million development milestone under Xilio's license agreement...
Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumorsAc...
Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $...
Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are exercise...
Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno...